A Multicenter, Randomized, DoubleBlind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pedia

Clinical Trial Grant

Duke Scholars

Principal Investigator Klaus-Georg Erich Werner Pediatrics, Neurology

Administered By

School of Medicine

Awarded By

Teva Branded Pharmaceutical Products R&D, Inc

Start Date

January 4, 2022

End Date

January 31, 2027

Administered By

School of Medicine

Awarded By

Teva Branded Pharmaceutical Products R&D, Inc

Start Date

January 4, 2022

End Date

January 31, 2027